Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.7 BRL | -1.17% | -0.53% | -2.83% |
Apr. 23 | Edwards Lifesciences Corporation: The story continues | |
Apr. 23 | Pfizer vs Moderna battle over COVID vaccine patents begins in UK | RE |
Sales 2024 * | 59.96B 308B | Sales 2025 * | 62.57B 321B | Capitalization | 149B 765B |
---|---|---|---|---|---|
Net income 2024 * | 6.75B 34.61B | Net income 2025 * | 9.29B 47.66B | EV / Sales 2024 * | 3.27 x |
Net Debt 2024 * | 47.04B 241B | Net Debt 2025 * | 41.91B 215B | EV / Sales 2025 * | 3.05 x |
P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
14
x | Employees | 88,000 |
Yield 2024 * |
6.44% | Yield 2025 * |
6.61% | Free-Float | 59.09% |
Latest transcript on Pfizer Inc.
1 day | -1.17% | ||
1 week | -0.53% | ||
Current month | -3.44% | ||
1 month | -1.86% | ||
3 months | -4.32% | ||
6 months | -12.63% | ||
Current year | -2.83% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 33.7 | -1.17% | 1,082 |
24-04-22 | 34.1 | +0.44% | 11,206 |
24-04-19 | 33.95 | +2.04% | 7,749 |
24-04-18 | 33.27 | -0.54% | 2,758 |
24-04-17 | 33.45 | -1.27% | 6,504 |
Delayed Quote Sao Paulo, April 23, 2024 at 04:05 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.92% | 672B | |
+27.17% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.45% | 217B | |
+5.94% | 199B | |
-8.47% | 204B | |
-4.99% | 147B |
- Stock Market
- Equities
- PFE Stock
- PFIZ34 Stock